- Home
- Solutions
- By Diseases
- Congenital Ophthalmic Diseases
- Anophthalmia
Anophthalmia is a rare congenital condition characterized by the complete absence of ocular tissue, presenting a significant challenge in both diagnostics and therapeutics. As a research services provider, Protheragen is committed to providing one-stop solutions for anophthalmia diagnostics and therapeutic development.
Anophthalmia is a rare and severe congenital eye defect characterized by the complete absence of the ocular globe. This condition can occur in isolation or as part of a broader syndromic presentation. Anophthalmia is estimated to affect 1 in 30,000 live births, making it one of the rarest developmental eye disorders.
Fig.1 The genetics of early optic vesicle development. (Harding P., et al., 2019)The underlying causes of anophthalmia are complex, with both genetic and environmental factors playing a role. Genetic alterations, including chromosomal abnormalities and monogenic mutations in over 90 identified genes, are a major cause. These genes often encode transcription factors involved in early eye development or components of the retinoic acid signaling pathway. Environmental insults, such as gestational infections, maternal vitamin A deficiency, and exposure to certain drugs, can also contribute to the development of anophthalmia.
Genetic Screening
Genetic diagnostics play a pivotal role in the early detection of anophthalmia. Microarray and whole-exome sequencing (WES) are advanced techniques used to identify pathogenic variants associated with the condition. These methods have significantly improved the diagnostic yield, particularly in syndromic cases. For instance, WES has been instrumental in identifying mutations in genes like SOX2 and OTX2, which are commonly associated with severe forms of anophthalmia.
Small Molecule Therapies
The development of small molecule drugs offers a promising avenue for the treatment of genetic disorders like anophthalmia. Ataluren, a drug that targets in-frame nonsense mutations, has shown potential in postnatal treatment by interfering with ribosomal fidelity. This mechanism allows for the production of full-length functional proteins, demonstrating the developmental plasticity of the eye.
Stem Cell Therapies
Stem cell technology, particularly induced pluripotent stem cells (iPSCs), holds great promise for modeling diseases and developing novel therapies. Disease modeling with iPSCs allows for the investigation of pathogenic mechanisms in a dish, providing a platform for drug screening and therapy development. This approach has shown potential in understanding the role of key genes like VSX2 in maintaining the neural retina identity, which is crucial for optic vesicle development.
Gene Therapies
The genetic basis of anophthalmia is complex, with over 90 identified associated genes. Key among these are transcription factors such as SOX2, OTX2, and PAX6, which play crucial roles in early ocular development. Mutations in these genes can lead to the arrest of eye formation, resulting in anophthalmia or microphthalmia. Understanding these genetic pathways is fundamental to the development of targeted therapies.
At Protheragen, we are committed to advancing the field of anophthalmia research through cutting-edge diagnostics and therapeutics development services. Our comprehensive approach includes:
At the foundation of our therapeutic development pipeline is a robust preclinical research program. Protheragen leverages advanced in vitro and in vivo models, including patient-derived iPSCs and animal models, to investigate the underlying mechanisms of anophthalmia and evaluate the efficacy and safety of potential therapies. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.